论文部分内容阅读
目的调查在南京大学医学院附属鼓楼医院进行孕前筛查和产前普查的育龄女性的TORCH感染情况,分析不同季节、不同年龄段人群TORCH感染的特征,为该地区育龄女性的预防保健提供参考依据。方法采用酶联免疫吸附试验对3 340例孕前及孕期妇女进行血清中TORCH特异性抗体IgM、IgG检测,根据季节、年龄分组比较TORCH不同病原体感染率的差异。结果 3 340例受检者中总IgM阳性率为2.6%,巨细胞病毒(CMV)的IgM阳性(近期感染)率和IgG阳性(既往感染)率分别为1.05%和65.14%;弓形虫(TOX)、风疹病毒(RV)和CMV IgM的检出率均在夏季最高,夏季TOX和RV IgM阳性率分别为1.38%和1.30%,显著高于其他3个季节(P<0.01);20~25岁年龄组TOX IgM检出率(1.08%)显著高于26~30岁组(0.36%)(P<0.05);CMV IgM的阳性率在20~25岁组最高,为1.49%,与31~45岁组(0.47%)差异有统计学意义(P<0.05)。结论育龄女性TORCH感染以CMV最多见,相关病原体感染具有季节性和年龄差异,有必要有针对性地加强预防保健,并积极做好TORCH特异性抗体的检测和监测。
Objective To investigate the TORCH infection among women of childbearing age at pre-pregnancy screening and prenatal screening at Drum Tower Hospital affiliated to Nanjing University Medical College, and to analyze the characteristics of TORCH infection in different seasons and different ages so as to provide reference for prevention and treatment of women of childbearing age in this area . Methods Serum TORCH-specific IgM and IgG were detected in 3340 pre-and post-pregnancy women by enzyme-linked immunosorbent assay (ELISA), and the differences of infection rates among different pathogens of TORCH were compared according to season and age. Results The positive rate of total IgM in 3 340 cases was 2.6%. The rates of IgM positive (recent infection) and IgG positive (previous infection) of cytomegalovirus (CMV) were 1.05% and 65.14% respectively. Toxoplasma gondii ), Rubella virus (RV) and CMV IgM were the highest in summer. The positive rates of TOX and RV IgM in summer were 1.38% and 1.30% respectively, significantly higher than those in the other three seasons (P <0.01) The detection rate of TOX IgM in the age group was significantly higher than that in the 26-30 age group (1.08%, P <0.05). The positive rate of CMV IgM was the highest in the age group of 20-25 years (1.49% The 45-year-old group (0.47%) had significant difference (P <0.05). Conclusion TORCH infection in women of childbearing age is the most common with CMV. The related pathogen infection has seasonal and age differences. It is necessary to strengthen the prevention and health care in a targeted manner and to detect and monitor TORCH specific antibodies actively.